What is the maximum number of days between eractuzumab treatments?

Eranatamab (Elranatamab) is a bispecific T-cell-ligated antibody targeting BCMA (B-cell maturation antigen) and is indicated for patients with relapsed or refractory multiple myeloma (RRMM). The treatment interval arrangement is based on the strategy of gradually increasing the dose and safety evaluation in clinical studies. The goal is to ensure the efficacy while minimizing the risk of immune toxic side effects such as cytokine release syndrome (CRS) and immune-related neurotoxicity (ICANS).

Before officially entering treatment, patients need to complete the dose escalation phase: Inject 12mg on the 1st day, 32mg on the 4th day, and the official treatment dose of 76mg on the 8th day. This stage is the "introduction period", which emphasizes the gradual establishment of drug tolerance. In particular, the first two injections require hospitalization for 48 hours and 24 hours of monitoring respectively. This design is designed to closely observe whether the patient develops severe inflammatory reactions or central nervous system symptoms.

After entering the 9th day, the patient started the standard dosage phase, which was an injection of 76mg once a week, which lasted until the 24th week. After the 25th week, if the patient shows good disease control response to the treatment, the doctor can adjust the injection interval to once every two weeks based on efficacy and tolerability. This means that, on the premise that the treatment is effective and no serious adverse reactions occur, the maximum treatment interval of eractuzumab can be extended to 14 days (i.e., injection every two weeks), and this interval can last until the disease progresses or the patient cannot tolerate it.

It is important to emphasize that extending the treatment interval is not suitable for all patients. This strategy may only be considered when stable disease control is achieved with previous treatment without severe immune-related toxicity. Therefore, during the actual medication process, patients should strictly follow the individualized treatment plan formulated by the doctor for drug injection, and cooperate with the monitoring of blood images, inflammatory markers and immune indicators before and after each treatment.

Reference materials:https://www.drugs.com/mtm/elranatamab.html